Part two of a three-part series aimed at helping drug and device manufacturers better navigate and understand the Veterans ...

Criminal enforcement of the Foreign Corrupt Practices Act was paused on February 10 by a Trump administration executive order ...

In the dynamic pharmaceutical industry, successful product launches are critical to business success. For small and midsized biotech firms, where the reliance on a few key assets is high, the stakes ...

Dr. Scherer’s commitment to oncology patients took him from medical practice to research to helming 3T Biosciences, which is developing a novel T cell targeting platform.

Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and ...

Established in 1997, Ergomed is a global leader in delivering specialized services in oncology, rare disease, and complex trials to the pharmaceutical and biotech sectors. Our comprehensive support ...

Tax policy shifts can directly affect corporate structure decisions, overall business strategy, and the ability to allocate ...

One of the biggest incentives for developing new therapies for rare pediatric cancers is the FDA’s rare pediatric disease Priority Review Voucher (PRV) program. If a drug in development meets the ...

In 2021, I explored the impact of COVID-19 on the biotech sector in the article “Private Equity and SPACs in the Biopharma and Biotech Landscape.” The results were surprising: In 2024, global ...